Nuclear receptors and Ion channels

Nuclear receptors and ion channels represent two distinct and major classes of therapeutic targets. Nuclear receptors are a superfamily of ligand-dependent transcription factors that regulate gene expression in response to lipophilic molecules like steroids and thyroid hormones, playing critical roles in metabolism, development, and homeostasis (Mangelsdorf et al., 1995, Cell). Ion channels are pore-forming membrane proteins that allow the selective passage of ions across cell membranes, essential for establishing resting membrane potential, generating action potentials, and regulating cell volume (Alexander et al., 2021, British Journal of Pharmacology). While both are vital for cellular signaling, they operate through fundamentally different mechanisms: nuclear receptors primarily influence the transcriptome, whereas ion channels mediate rapid electrical and chemical changes. Drugs targeting nuclear receptors include corticosteroids and selective estrogen receptor modulators, while ion channel modulators include local anesthetics and calcium channel blockers. Both classes are among the most successful targets in the history of the pharmaceutical industry, accounting for a significant portion of all FDA-approved drugs. Because this entry combines two broad and unrelated protein superfamilies, it does not represent a single specific therapeutic target.

Other names

Nuclear receptor superfamilyIon channel superfamilyLigand-activated transcription factorsPore-forming membrane proteins

Nuclear receptors function as ligand-activated transcription factors that bind to specific DNA sequences to regulate the expression of target genes (Mangelsdorf et al., 1995). Ion channels act by opening or closing a central pore in response to chemical or electrical signals, allowing the rapid flux of ions across the plasma membrane or organelle membranes (Alexander et al., 2021).